Streptokinase-induced, antibody-mediated platelet aggregation: A potential cause of clot propagation in vivo  by Vaughan, Douglas E. et al.
CASE REPORTS 
Streptokinase-Induced, Antibody-Mediated Platelet Aggregation: A 
Potential Cause of Clot Propagation in Vivo 
WUGLAS E. VAUGHAN, MD, JAMES M. KIRSHENBAIJM, MD, FACC. 
JOSEPH LOSCALZO, MD, PnD, FACC 
Bos,on, Mossochuse,,s 
The early administration of streptokinase in acute tttyocar- 
dial infarction has gained widespread acceptance as a means 
of preserving ventricular function and improving survival in 
selected groups of patients (1.2). These beneficial effects are 
mediated through the repelfusion of ischemic myccardium 
that occurs after successful thmmlwlysis in the “infarct” 
artery (3). Repelfusion can lx expected to occur in 575% of 
patients whop receive intracomnaty streplokinase and in 
approximately 6Q?& of patients who receive streptokinase 
intravenously (&9). 
Thmmbolytic failure can occur for several reasons. Not 
all patients experiencing an acute myocardial infarction have 
an identifiable thmmbtts in the infarct artery. Angiogtaphic 
data (10) indicate that nearly 20% of patients are in this 
category and. accordingly. would not he expected to benefit 
from the administration of a thrombolytic agent. Achieve- 
ment of a systemic “lytic” state is a prerequisite for thera- 
peutic clfcctiveness in patients who receive intravenous 
rtreptokinase (I I) and may also be nscerrary for patients 
receiving intracomtwy infusions IL?). Failure to achieve a 
systemic lytic state is most commonly due to elevated levels 
of andstreptokinane antiwdies (13), but can also be due to 
plasminogen deficiency, dysplasminogenemias or elevated 
levels of alpha-2 antipla~min (14). 
Antistreptakinase antibodies are ubiquitous in adult hu- 
mans and circulate as immunologic evidence of previous 
infection with beta.hemolytic streptococci (IS). Very high 
titers of antistreptokinaw antibodies can b: seen within days 
of an acute streptouxcal infection or after the administra- 
tion of streptakinase (16). Few individuals have such high 
titers of antistrqtokinase antibodies that the dose of strep- 
iokinasc used in intravenous protocols may ttot overcome 
the neutralizing erect of the antibodies (13). Antistreptoki- 
naw antibodies have generally been regarded as of little 
consequence when strepmkinase is delivered through the 
intracoronaiy mute. We present evidence that streptoki- 
nsse-specific antibodies can mediate platelet aggregation in 
the presence of streptokinase in vitro and may potentially be involving the anterior, apical and inferior walls gradually 
responsible for clot propagation in viva developed. Subsequent laboratory studies included ott anti- 
streplolysin 0 titer of 200 IUlml (normal 0 to 200) and a 
Case Report 
transient decrease in platelet count from 363,CQil mm’ on 
admission to 179,000 on hospital day 2. 
Cttoieat reatorw. A 54 year old roan with no prior history 
of coronary disease was hospitalized while experiencing an 
acute myowdial infarclion. His past medical history was Methods 
remarkable only for an episode of acute rheumatic fever in Thmmbolytic and atttiplstekt agents. Streptokinasc (Ka- 
his youth. On the evening of admission, he experienced, bikinase), purified human plasminogen and Ii-D-valyl-L- 
while working. the sudden onset of substemal chest pain leucyl-L-lysine-pnitmanilidc dihydrochloride (S-2251) were 
accompanied by nausea and diaohoresis. He was trans- obtained from KABl Diazttortics through Helena LaboratU- 
oorted-to the hbspitrd acd wrivei in the emergency room ries. Urokinasc (Abboki&e) was purchased from Abbott 
within 30 min of the onset of pain. On examination he Laboratories. Recombinant human tissue-type plasminogen 
appeared dyspneic and diaphoretic. The pulse rate was 95 activator (Activasc) was kindly provided by Genentech, Inc. 
beatslmin and blood pressure was SO/50 mm Hg. Bibasilar Diethylaminoethyl-cellulose (DE-Q was purchased from 
roles were present and the iuzolar venous pressure war Whatman Biochemicrds, Ltd.. Kent, Euplaod. Luciferax 
estimated 16 be 10 cm H,O. -&rdiac exam&ion revealed 
the presence of an S, gallop, and a grade 216 holosystalic 
murmur that radiated toward the axilla. Laboratory studies 
included a namtal blood cottot and electrolytes. A chest 
X-ray likn demonstrated pulmonary edema with B nomtal- 
sized cardiac silhouette. The initial electrocardiogram (ECG) 
revealed sinus rhythm with 2 mm ST segment elevation in 
leads II. 111 and aVF consistent with transmural infcrio: 
myoardial &hernia. 
Intracorottary Btmmkalyiie ~lterapy. He was immediately 
transferred to the cardiac catheterization laboratory where 
initial hemodynamic recordings included the following pres- 
sores (mm Kg): right atrium (mean) 15, right ventricle 40/16, 
eolmonarv arterr 40121 and otdmonarv caoillarv wedee 
&tean) 3i Corn&y aogiograp& revealed the pre&tce oia 
Iw% stenosis of the proximal left anterior descending coro- 
nary artery as well as a 90% stenosis of the distal right 
coronary. After completion of the angiographic studies, the 
patient’s chest pain iatensified and reiojection of the left 
coroowy system now revealed a total occlusion of the left 
at~terior dewending coronary artery. Several attempts to 
reopen the vessel with coronary aogioplasty were ttnsuc- 
cessful. The patient then received a bolus of 20,OMl U of 
streptokinase into the left anterior descending anery through 
o 2F catheter followed by an infusion of 4.oW Ulmin over I 
h. 
Rwor left coronary angiography sr 15 min inrends 
cle.wly demonstrated the gradual appearance and propaga- 
tion of clot from the left anterior descending into the left 
main coronary artery as the intracomnary stre$ok’nase was 
infusing (Fig. I). On removal of the catheter. thrombus 
entered and transiently filled the lumen of the left circumflex 
coroow artery. which on multiple previous views had ken 
normal. ‘Ibis was associated with immediate hemadynamic 
deterioration; the expeditious augioplasty of the left circum- 
Rex artery reestablished Row and hemodynamic stability. No 
forther imerwntioos were undertaken and a large infarction 
(Chromolume X395) was purchased from Chronolog, Inc. 
Goat antihuman IgG Fab was purchased from Miles Scien- 
tific. Aprotinin was obtained from Sigma Chemical Corp. 
IgG prqmra1ion. Plasma fmm the index patient was 
collected and IgG isolated using a combination of ammonium 
sulfate wci~itatiou and ion exchange chromatography (17). 
Plrpmkafit oreotontioo. Human olasminoeen was ore- 
pared from &sh’ h&m plasma by &tity chr&to&phy 
on lysine-Seohamse occordina to the method ofDeut.wh and 
Mertz (IS). 
A&tie oteBto&. Plasmin activity ws measured using 
the chromogenic substrate S-2251 ( 9,. Protein detemtitta- 
tions were performed according to the method of Lowry et 
al. (20). F‘&ipitatiog antibodies directed against strep&- 
ease and the streptokinase-plasminogen complex were mea- 
sured using a malifw.tion of the semiquatttitative method of 
Spottl sod Kaiser (16). The streptokinase-neuualbingeapae- 
ity of plasma and immuthxlobolin samples was measured 
using & inhibition of lysis method (21) ibiohletieox, char- 
bonnieres les Baina, France). Direct antiplatelet cm&dies 
were measured by an immunofluoresence method (22). 
Ant&t prepamtiio. Fresh platelers were obtained fmm 
the patient and from 15 normal volunteers. Venous blood 
was drawn into 13 mM ttisodittm citrate (nine parts bkmd to 
one part citrate). Platelet-rich plasma was prepared by 
cenlrifugation at I20 g for IO min at 22oC. The top two thirds 
of the platelet-rich plasma was removed for aggregation 
experiments. Platelets were kept at 22°C for <I h before use. 
Washed ok&let susoensions were oreoared accordion to the . . 
melhod of Ardlic ct al. and resuspended in divalent cation- 
free Tyrode’s buffer immediitelv before use (231. 
Platekt aggregation. PlateI& in plntelet-rich plasma 
were monitored for aggregroion at 37°C with stirriog al 900 
rpm by a standard neuhelomett’ic method usine a dual 
channel aggregometer (i4). Typical experiments were per- 
fortoed with 40(1 &I of plateletlich plasma. and aggregation 
was monitored after the addition of 2.500 to 15,0(H) U/ml 
Fiwre 1. Retmgrade thrombus progression during in- 
trecomnew infusion of srrepiokinase. Upper peeI 
tan&ram and Iracing> shows I&l anterior dwellding 
coronary aitcry CLAD, occturion before initiation of 
slwtokinax infurmn. The 2F infusion catherer con- 
tains a radiopaque marker. whisk eppeal~ es de dot in 
the drawing at rigkr. Lma pe& demonswater thram- 
bus progression i to the tell main comnary artery es 
seen at 45 rni” into ,he st,eDtokinssP infusion. LCX = 
left circumt?er coronary a& 
streptokinase or equivalent concentrations of urokinase or 
recombinant issue-tyDe vlasminopen activator. Mixinn ex- 
periments were also.t%ormed u&zing 350 ~1 of pla&t- 
rich plasmafromcontrols, to which wasaddedeither5Ofil of 
plasma or purified IgG from the index patient. Similar 
exwhttcnts were performed in ulatelet-rich Qlasma in the 
preoenceand ab&e ofgwt an&men IgG F&I. The firefly 
luminescence method was ueed for detemG.ation of aden+ 
sine triphasphate secretion during platelet aggregation (25). 
Platelet aggwgtion in whale bled was performed According 
to an imwIance method (26). 
Washed ploreler exprrimenrs were performed in cwettes 
containing 12.5 run calcium chloride with a final platelet 
count of I.5 x lo’ platelets/pi. In these experiments, 25 @I of 
purified plasminagen to.1 mg/ml final concentmtion). 25 ~1 of 
streptokinase (13,888 U/ml) and IO0 ,ul of purified IgG from 
the index patient (I.2 mglml) wereadded to3oopl of washed 
platelets and the suspension was monitored for aggregation. 
Platelet ~egnlim induced by sIrept&ttnw. The addi- 
tion of streptokinase to platelet-rich plasma fmm the index 
Patient Qrwtuced a noid increase in light transmittance 
indicative of aggregation (Fig. 2A). This at& occurred in I of 
15 control subjects. The streptokinase-induced platelet ag-
Bregation seen in platelet-rich plasma from the patient oc- 
curred after a lag phase of approximately I min. Awegatian 
was observed with concentrations of streptokinase between 
2.50(1 and 25.000 U/ml. Similar results were obtained in 
whole blood. Luminescence aggregometry demonstrated 
that platetm secretion accompanied aggregation induced by 
rtreptokinare (Fig. 26). 
Miig exm. In I4 of I5 control subjects. w 
platelet aggregation was observed in platelet-rich plasma 
with addilion of streptokinase. ARer the addition of plasma 
or fSG from the index patient to these previously mxxeec- 
Figme 1. dreptokinase-induced platekt awegalionand secretion. 
In the YW we+ t.,,, Qtarck, aggregatian is seen after the 
addilian of nreptektnase trk) to a final concentration f 5,ooO U/ml 
in platelet-nch phsn!a from the index Qatient. Streptokinase- 
induced platelet aggregation was accompanied I-/ wrelion of 
denas,ne ,,iphospha,e (AI?,, as rh._wn in the simullaneously 
obtained companion tracing tltt. 
live control subjects, however, aggregation occurred in all 14 
instances. When these experiments were performed in the 
prcscncc of 176 &ml goat antihuman IpG Fab. the aggrc. 
gatoty response was completely inhibited. In mixing cxpcr- 
iments using normal washed Plaelels, aggregation predict- 
ably occurred in the presence of platelets (I.5 X IOSII& 
plasminogen (0.1 mdml). streptokinase (13,888 U/ml) and 
IgG (I.2 ms/ml) from the index patient. Aggregation was 
observed after the addition of all four constituents, regard- 
less of the order of addition. 
Qusntttattve antibody nwawements. Plasma irom the 
index patient had astreptokinasc-neotratiziog capacity of 20 
U/ml at the time of hospitalization. This increased to I80 
U/ml by hospital day IO. and 6 months after hospitalization 
the patient’s titer rctumed to baseline. flasma from each 
time period WCS equally patent in supporting platelet aggrc- 
gation in the presence of streptokinase. Plasma from the 0°C 
positive Control subject had B streptokinase-neutralizing 
capacity of 1280 U/ml. Direct antiplatelet antibodies and 
complement WCR identified in the plasma of the index 
patient only after the addition of strcptokinase. 
Lack of &et of omkitwe and remmbittsnl t&we-type 
ptasmbmgen ~etivctor. No evidence of platelet aggregation 
was Seen after the additios of otbcr plasminogen activators. 
Urokinase and tissue plasminogen activator in concentra- 
tions up to l2.5W U/ml were used in these expctiments and 
both failed to initiate platelet aggregation in platelet-rich 
plasma from the patient or from any of the I5 control 
subjects. 
Reiatioa to plasmin activity. In expcrimentr using Igii 
fmm the index patient added to platelet-rich plasma, strep- 
tokinase was capable of inducing platelet aggregation even in 
the presence of aprotinin (250 to 500 U/ml). These concen. 
trations of aprotinin were sufficient to eliminate entirely the 
amidolyric activity of plasmin (as quantified with the cbro- 
mogenic substrate S2251) and failed to appreciably alter the 
time CourSc or extent of platelet aggregation induced by 
streptokinase. In addition. plasminogen activation by strep 
tokinase was not inhibited by this Igti fraction. 
Discussion 
Our results demonstrate that the patient described herein 
possesscr a circulating antibody that promotes platelet ag- 
w&on spccifica!ly and predictably in !hc presence ofborh 
streptokinase and plasminogcn. We hypothesize that this 
paradoxically resulted in localized clot propagation duriy 
the administration of intracomncry streptokinax and was 
nearly catastrophic. 
Mechanistic analysis. Plasmin is foormed by the proteoly- 
tic action of plasminngen activators n circulating plasmino- 
gcn and is known to cxcn a variety of effects on platcIcts. At 
low doses (<0.7 U/ml). plasmin can inhibit human platelet 
agsregation and thromboxane A2 production in vitro (27). At 
higher doses, plasmin can eewe platelet aggregation and 
Secretion (28.29). The aggregation we observed in platelet- 
rich plasma from our patients and in mixing experiments 
occurred despite hhibilion of the proteolytic activity of 
Plasmin, and inrtead required the presence of antibody, 
plasminogcn and streptokinase. In fact. our Studies indicate 
that cc exees~ of antihuman IgO Fab was capable of inhib- 
iting strcptokinase-induced platelet ag8rcgation in vitro, 
providing even more powerful evidence for the direct mlr of 
antibody in the a@regation response. Importantly, the anti- 
body failed to inhibit plasminogen activation by streptoki- 
nase, showing !hat hen is a discordance between Strepto- 
kiinasc-neutralizing capacity and induction of platelet 
aggregation bythisantibody. The streptokinase pecificity of 
this phenomenon is further shown by the observation that 
neither urokinase nor tissue plasminogen activator initiated 
platelet cggregation in vitro. 
Slreprokinnse ocrivares &wm’nogen by binding 10 b and 
impmtbtg enzymofic activity 10 the complex. Plasminogen 
binds to the platelet surface (30). and one group (31) has 
shown that the activation of plasminogen by strcptokinase 
occttrs much more rapidly on the platelet surface than in 
plasma. Taken together. these data suggest hat the Strepto- 
kioase-plasminogen comp~cx binds to the platelet Surface 8s 
well. Given these data and the IgG dependence of strepto- 
kinase-induced platelet aggregation in our patient, we pos- 
tulate that at least two intetrelated. but not necesssrily 
WnSCCUtiVc, Steps arc involved in the platelet aggregation 
rcspatsc: I) plasminogen and streptokinase binding to the 
platelet surface, and 2) bivalent antibody binding to Strcpto- 
kinase or the streptokinase-plasminogen complex on the 
platelet surface with subsequent platelet aggregation. This 
mechanism is quite analogous to that of hcparin-asswiatcd 
thrombosis, in which it appears that hcparin binds to a 
platelet membrane component and induces the formation of 
antibody to the complex. Bivalent antibody presumably 
binds to platelets in the prcscncc of hcparin and thereby 
induces aggregation (32). The fact that antiplatelet antibodies 
were detectable in the blood ofour index patient only in tbe 
prcScncc of streptokinax lends considerable support to this 
Co”Ccpt. 
Clinical Significance. The incidence of strep:&inase- 
mediated platelet aggregation is not known at the cumnt 
time. Screening I5 normal volunteerS. wcfotmdevidencefor 
a Similar phenomenon in I individual. Although this sample 
size is small, it appears that this phenomenon may not be 
rare in the general population. The clot propa8ction ob 
served in our patient was subtle and only recognized after 
careful analysis of the coronary aogiograms. Interestingly. 
Amery et al. (33) reported a 9% incidence rate of throm- 
bocmbolic complications, coincident with the intravenous 
infusion of strcptokinase, in 85 patients treated for periph- 
eral vascular occlwion. Importantly, these events occurred 
at Sites remote from the involved limbs. Others (34) have 
reported both the primary occlusion and transient reopening 
followed by reocclusion of eoronarv aneries while intraw- 
ronray streptokinase was administered. We can only specu- 
late that these events are mediated by a amilar mechanism 
as in our patient. The basic concern in describing such a 
phenomenon is that it is difficult to predict when and in 
whom it will occur. Our index patient had a history of 
rheumatic fever and this certainly increases the potential for 
prior sensitization to streptokinare. At the time nf presenta- 
tion, however, he hadanormal titerof neutralizingantistrep- 
tokinaae antibodies. The one contml subject who also man- 
ifested slreutokinase-induced &delet aweeation had a 
history of neither recwent stre&xcccal rife&n nor pnor 
ex!~osure to rtreptokinare (although he did have a signifi- 
cantly elevated titer of antistreptokinase antibodies). Previ- 
ous rqmtr (16) have suggested that approximately 10% of 
hospitalized ratients have elevated titers of antistreotoki- 
I& zmtibod~es, ar.d one group (35) found a corr&tian 
between rtreptokinase-induced platelet aggregation in vitro 
and titer ofantistreptakinase antibody. In contrast, our data 
sttggest hat a qualitative difference exists between strepto- 
kinase-neutralizing antibodies and platelet-aggregating anti- 
badies in wr index patient. 
Reeommrndatiow The sinniticance of streotokinase- 
induced. antibody-mediated platelet aggregation ;emains to 
be defined. It seems unlikely that our patients are immuno- 
logically unique in this regard, given the ubiquity of anti- 
streptokinase antibodies in the general population. Strcpto- 
kinase-induced clot propagation or thromboembolism ay 
be underdiagnosed because it is not generally recognized 
as a potential complication of the drug. Until further data 
become available. we recommend very careful screening 
of patients to determine those who an in fact, acceptable 
candidates for streptokinase administration. Optimal screen- 
ing should include measuring platelet aggregation on 
addition of streptokinase to platelets in platelet-rich 
plasma. Patients with an antecedent history of repeated or 
recent streptocoecal infections or prior exposure to strepto- 
kinase should be excluded. Unfortunately. it may not be 
possible to perform an adequate xrcening of patients who 
arrive in need of the urgent administration of a thrombOlytic 
agent, and this argues for the use of nonimmunogenic drugs 
(tissue plasmitwgen activator or urokinase) exclusively in 
the emergent situation. 

